SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    DesRoches CM, Campbell EG, Rao SR, Donelan K, Ferris TG, Jha A, et al. Electronic health records in ambulatory care: a national survey of physicians. N Engl J Med 2008; 359: 5060.
  • 2
    Anderson MR, and the American College of Rheumatology Committee on Rheumatologic Care. Electronic medical records for the physician's office. URL: www.rheumatology.org/products/coding/03emr_toc.asp.
  • 3
    Jha AK, Ferris TG, Donelan K, DesRoches C, Shields A, Rosenbaum S, et al. How common are electronic health records in the United States? A summary of the evidence. Health Aff (Millwood) 2006; 25: 496507.
  • 4
    American College of Rheumatology. Quality measures. URL: www.rheumatology.org/practice/qmc/.
  • 5
    Deal CL, Hooker R, Harrington T, Birnbaum N, Hogan P, Bouchery E, et al. The United States rheumatology workforce: supply and demand, 2005–2025. Arthritis Rheum 2007; 56: 7229.
  • 6
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 338190.
  • 7
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 2639.
  • 8
    Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 14439.
  • 9
    Prevoo ML, Kuper IH, van 't Hof MA, van Leeuwen MA, van de Putte LB, van Riel PL. Validity and reproducibility of self-administered joint counts: a prospective longitudinal followup study in patients with rheumatoid arthritis. J Rheumatol 1996; 23: 8415.
  • 10
    Gardiner PV, Bell AL, Taggart AJ, Wright G, Kee F, Smyth A, et al. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis [letter]. Ann Rheum Dis 2005; 64: 5067.
  • 11
    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 44854.
  • 12
    Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute-phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796806.
  • 13
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 14
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 15
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.